Top 5 CRISPR Stocks To Buy

3. Intellia Therapeutics, Inc. (NASDAQ:NTLA)

Number of Hedge Fund Holders: 39

Intellia Therapeutics, Inc. (NASDAQ:NTLA) is a genome editing company that focuses on developing curative therapeutics. Their programs include in vivo treatments for diseases such as transthyretin amyloidosis and hereditary angioedema, as well as ex vivo treatments for acute myeloid leukemia. They also offer tools that utilize the CRISPR/Cas9 system. The company also has proprietary programs that aim to develop engineered cell therapies for cancer and autoimmune diseases. It is one of the top CRISPR stocks to buy. 

On April 13, Canaccord analyst Whitney Ijem gave Intellia Therapeutics, Inc. (NASDAQ:NTLA) a Buy rating and a price target of $66. The analyst said that while Intellia Therapeutics, Inc. (NASDAQ:NTLA)’s focus on in-vivo gene editing in large, rare indications may not be the fastest path to the clinic compared to other early CRISPR peer companies, the company’s “methodical approach has paid off.” The analyst noted that Phase 1 data from both lead program NTLA-2001 in ATTR and wholly-owned NTLA-2002 in HAE look promising on the safety and efficacy side. Furthermore, progress through Phase 2 and into pivotal studies over the next 6-12 months should continue to provide value creation opportunities, Ijem told investors in a research note. 

According to Insider Monkey’s fourth quarter database, 39 hedge funds were bullish on Intellia Therapeutics, Inc. (NASDAQ:NTLA), compared to 36 funds in the prior quarter. Cathie Wood’s ARK Investment Management is the biggest position holder in the company, with 9.4 million shares worth $328.7 million. 

Carillon Tower Advisers discussed its stance on Intellia Therapeutics, Inc. (NASDAQ:NTLA) in its Q2 2021 investor letter.

“Intellia Therapeutics is a clinical-stage genome editing company focused on the development of proprietary, potentially curative therapeutics. The company’s stock soared after announcing positive interim data from an ongoing phase 1 clinical study of its in vivo gene editing candidate, which is being developed as a single-dose treatment for hereditary transthyretin (ATTR) amyloidosis. This specific form of therapy would be the first of its kind resulting in the precision editing of a gene in a target tissue in the human body.”